Home › Compare › CMRAW vs VICI

CMRAW vs VICI: Dividend Comparison 2026

CMRAW yields 10362.69% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMRAW wins by $78335784849600944.00M in total portfolio value
10 years
CMRAW
CMRAW
● Live price
10362.69%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78335784849600944.00M
Annual income
$76,876,438,600,915,240,000,000.00
Full CMRAW calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — CMRAW vs VICI

📍 CMRAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMRAWVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMRAW + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CMRAW pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMRAW
Annual income on $10K today (after 15% tax)
$880,829.02/yr
After 10yr DRIP, annual income (after tax)
$65,344,972,810,777,950,000,000.00/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, CMRAW beats the other by $65,344,972,810,777,950,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMRAW + VICI for your $10,000?

CMRAW: 50%VICI: 50%
100% VICI50/50100% CMRAW
Portfolio after 10yr
$39167892424800472.00M
Annual income
$38,438,219,300,457,620,000,000.00/yr
Blended yield
98.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CMRAW
No analyst data
Altman Z
-28.1
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMRAW buys
0
VICI buys
0
No recent congressional trades found for CMRAW or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMRAWVICI
Forward yield10362.69% ✓6.52%
Annual dividend / share$2.00 ✓$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3% ✓
Portfolio after 10y$78335784849600944.00M ✓$966.2K
Annual income after 10y$76,876,438,600,915,240,000,000.00 ✓$607,376.13
Total dividends collected$78238734181699024.00M ✓$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CMRAW vs VICI ($10,000, DRIP)

YearCMRAW PortfolioCMRAW Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$1,046,969$1,036,269.43$11,361$941.49+$1.04M → CMRAW
2$102,516,745$101,396,487.34$13,320$1,481.32+$102.50M → CMRAW
3$9,388,666,498$9,278,973,581.18$16,284$2,405.01+$9388.65M → CMRAW
4$804,237,430,573$794,191,557,419.90$21,040$4,071.78+$804237.41M → CMRAW
5$64,440,729,401,315$63,580,195,350,601.93$29,209$7,285.49+$64440729.37M → CMRAW
6$4,830,127,690,198,710$4,761,176,109,739,303.00$44,443$14,006.51+$4830127690.15M → CMRAW
7$338,693,420,711,903,550$333,525,184,083,391,000.00$75,822$29,512.55+$338693420711.83M → CMRAW
8$22,219,525,310,042,270,000$21,857,123,349,880,533,000.00$148,733$69,726.75+$22219525310042.13M → CMRAW
9$1,363,874,998,771,683,700,000$1,340,100,106,689,938,500,000.00$344,394$189,413.75+$1363874998771683.50M → CMRAW
10$78,335,784,849,600,940,000,000$76,876,438,600,915,240,000,000.00$966,234$607,376.13+$78335784849600944.00M → CMRAW

CMRAW vs VICI: Complete Analysis 2026

CMRAW — Stock

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Full CMRAW Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CMRAW vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMRAW vs SCHDCMRAW vs JEPICMRAW vs OCMRAW vs KOCMRAW vs MAINCMRAW vs NNNCMRAW vs EPRTCMRAW vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.